Analysis of the Role of T-cell Response in Patients With Atrial Fibrillation for Clinical Application

• Conditions: Atrial Fibrillation

• Registration Number: NCT02421900
• Lead Sponsor: Yonsei University

Brief Summary

The purpose of this study is 1) to characterize T-cell response in patients with atrial fibrillation, and 2) to analyze the changes of T-cell response after radio-frequency catheter ablation of atrial fibrillation. First, immune-phenotyping and cytokine profiling of T cells from patients with atrial fibrillation will performed. Next the difference of T-cell immunity among various type of atrial fibrillation patients will be analyzed. Finally the changes of T-cell response and cytokines after radio-frequency catheter ablation of atrial fibrillation will be assessed.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-04-01
• Study First Submitted: 2015-04-08
• Study First Submitted QC: 2015-04-15
• Study First Posted: 2015-04-21
• Status Verified: 2018-07
• Last Update Submitted: 2018-07-15
• Last Update Posted: 2018-07-17
• Primary Completion: 2020-03
• Study Completion: 2020-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Patients who consent with study
• patients with age more than19
• patients who undergoing catheter ablation of atrial fibrillation due to symptomatic, drug refractory atrial fibrillation

Exclusion Criteria

• Patients who do not agree with study inclusion
• Permanent AF refractory to electrical cardioversion
• AF with rheumatic valvular disease
• Patients with left atrial diameter greater than 60mm
• Patients with age less than 19
• Patient with malignant tumor and chronic infection disease
• Patient are given immune inhibitor and steroidal anti-inflammatory drug within 2weeks

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The frequency (%) of specific marker-expressing cells among CD4 or CD8 T-subsets	1 year	* Immunosenescence marker: CD28, CD57; * Activation marker: CD38, HLA-DR; * Differentiation marker: CCR7, CD45RA

Secondary Outcome Measures

Name	Time	Method
The frequency (%) of cytokine-secreting cells among CD4 or CD8 T-subsets	1 year	* Proinflammatory cytokine: IFN-gamma, TNF-alpha; * Cytotoxic molecule: granzyme B, perforin

Trial Locations

Locations (1)

Severance Cardiovascular Hospital, Yonsei University Health System; 🇰🇷 Seoul, Korea, Republic of